AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 116 filers reported holding AUDENTES THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 1.14 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $29,555,000 | +113.0% | 493,901 | 0.0% | 0.94% | +66.6% |
| Q3 2019 | $13,874,000 | -25.8% | 493,901 | 0.0% | 0.57% | -15.8% |
| Q2 2019 | $18,699,000 | -3.0% | 493,901 | 0.0% | 0.67% | -9.1% |
| Q1 2019 | $19,272,000 | +83.0% | 493,901 | 0.0% | 0.74% | +75.1% |
| Q4 2018 | $10,530,000 | -46.1% | 493,901 | 0.0% | 0.42% | -39.7% |
| Q3 2018 | $19,554,000 | -51.2% | 493,901 | -52.9% | 0.70% | -50.2% |
| Q2 2018 | $40,061,000 | -3.7% | 1,048,430 | -24.3% | 1.41% | -2.4% |
| Q1 2018 | $41,603,000 | +11.8% | 1,384,470 | +16.3% | 1.44% | -1.6% |
| Q4 2017 | $37,204,000 | -12.9% | 1,190,516 | -22.0% | 1.46% | -23.9% |
| Q3 2017 | $42,727,000 | +29.2% | 1,525,410 | -11.8% | 1.92% | +9.1% |
| Q2 2017 | $33,081,000 | +38.3% | 1,729,268 | +23.2% | 1.76% | +91.4% |
| Q1 2017 | $23,918,000 | -6.7% | 1,403,653 | 0.0% | 0.92% | -12.6% |
| Q4 2016 | $25,645,000 | +2.6% | 1,403,653 | 0.0% | 1.06% | -9.3% |
| Q3 2016 | $24,999,000 | – | 1,403,653 | – | 1.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $37,644,219,000 | 39.61% |
| Casdin Capital, LLC | 400,000 | $12,500,000 | 3.04% |
| Opaleye Management Inc. | 210,000 | $6,652,000 | 2.13% |
| Orbimed Advisors | 4,129,638 | $129,051,000 | 1.63% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,516 | $37,204,000 | 1.46% |
| Redmile Group, LLC | 929,326 | $29,041,000 | 1.26% |
| Cormorant Asset Management, LP | 337,876 | $10,559,000 | 1.10% |
| Perceptive Advisors | 781,309 | $24,416,000 | 0.81% |
| Rock Springs Capital Management LP | 525,000 | $16,406,000 | 0.74% |
| Virtus ETF Advisers LLC | 11,898 | $372,000 | 0.47% |